United States Biologics Contract Manufacturing Market is expected to reach US$ 36.4 billion by 2033 | Major key players - Wuxi Biologics, AGC Biologics, Lonza, KBI Biopharma.

Market Size and Growth:

The Biologics Contract Manufacturing Market size reached US$ 26.03 billion in 2024 and is expected to reach US$ 83.47 billion by 2033, growing at a CAGR of 14.0% during the forecast period 2025-2033.

The Biologics Contract Manufacturing Market refers to third-party service providers that develop, produce, and scale biologic drugs for biopharmaceutical companies. It covers manufacturing of monoclonal antibodies, vaccines, recombinant proteins, cell and gene therapies, and biosimilars. These organizations offer end-to-end services including process development, upstream and downstream production, formulation, fill-finish, and regulatory support, enabling drug developers to reduce costs, accelerate timelines, and meet global quality and compliance standards.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID): https://datamintelligence.com/download-sample/biologics-contract-manufacturing-market?sz

Recent Key Developments of United States:

✅ February 2026: WuXi Biologics opened a state-of-the-art plasmid DNA manufacturing plant in Massachusetts, targeting a 25% cost reduction for early-stage biologics development and attracting contracts from over 20 U.S. innovators.

✅ January 2026: Samsung Biologics, through its U.S. operations, secured a multi-year $300 million deal with a top pharma for large-scale production of biosimilars, boosting U.S. capacity utilization to near 90%. This reflects growing reliance on hybrid onshore manufacturing amid supply chain resilience efforts.

✅ December 2025: Leading contract manufacturer Lonza announced a $250 million investment in single-use bioreactor technology upgrades across its U.S. sites, enhancing scalability for complex cell and gene therapy biologics. Partnerships with several startup biotechs accelerated commercialization timelines.

✅ November 2025: A major U.S.-based CDMO expanded its biologics fill-finish capacity by 40% at a new facility in North Carolina to meet surging demand for monoclonal antibodies and gene therapies. This move supports faster turnaround for domestic biotech firms outsourcing production.

Recent Key Developments of Japan:

✅ February 2026: Chugai Pharmaceutical partnered with a U.S. firm for co-development of next-gen biologics, establishing a joint CMO venture in Osaka with modular cleanrooms for rapid scale-up of personalized medicines.

✅ January 2026: A consortium of Japanese CDMOs, led by CMIC Group, invested ¥20 billion in automated downstream processing tech, reducing purification times by 30% for antibody biologics and positioning Japan as Asia's hub for high-quality outsourcing.

✅ December 2025: Fujifilm Diosynth Biotechnologies expanded its Japanese facility in Kitakyushu by adding viral vector production lines, securing deals worth ¥15 billion from local and global clients focused on cell therapies.

✅ November 2025: Kyowa Kirin launched a new contract manufacturing division in Tokyo, specializing in mammalian cell line development for biosimilars, with initial capacity for 500 liters of production runs. Government subsidies under Japan's BioStrategy 2025 aided the initiative.

List of the Key Players in the Biologics Contract Manufacturing Market:

Wuxi Biologics
AGC Biologics
Lonza
FUJIFILM Diosynth Biotechnologies.
Thermo Fisher Scientific Inc.
KBI Biopharma
Vetter Pharma
Recipharm AB.
Abzena Ltd
Samsung Biologics
Eurofins CDMO
Catalent
Boehringer Ingelheim International GmbH

Speak to Our Analyst and Get Customization in the report as per your requirements: https://datamintelligence.com/customize/biologics-contract-manufacturing-market?sz

This Report Covers:

✔ Go-to-market Strategy.

✔ Neutral perspective on the market performance.

✔Development trends, competitive landscape analysis, supply side analysis, demand side analysis, year-on-year growth, competitive benchmarking, vendor identification, and other significant analysis, as well as development status.

✔Customized regional/country reports as per request and country level analysis.

✔ Potential & niche segments and regions exhibiting promising growth covered.

✔ Analysis of Market Size (historical and forecast), Total Addressable Market (TAM), Serviceable Available Market (SAM), Serviceable Obtainable Market (SOM), Market Growth, Technological Trends, Market Share, Market Dynamics, Competitive Landscape and Major Players (Innovators, Start-ups, Laggard, and Pioneer).

Segments Covered in the Biologics Contract Manufacturing Market:

By Product Type: Monoclonal Antibodies, Recombinant Proteins, Cell and Gene Therapies, Vaccines, Others.

By Platform: Mammalian, Microbial, Others.

By Application: Oncology, Metabolic Diseases, Autoimmune Diseases, Ophthalmology, Infectious Diseases, Cardiovascular Diseases, Others.

Regional Analysis:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Looking For Full Report? Get it Here: https://www.datamintelligence.com/buy-now-page?report=biologics-contract-manufacturing-market

Chapter Outline

⏩ Market Overview: It contains five chapters, as well as information about the research scope, major manufacturers covered, market segments, Biologics Contract Manufacturing market segments, study objectives, and years considered.

⏩ Market Landscape: The competition in the Global Biologics Contract Manufacturing Market is evaluated here in terms of value, turnover, revenues, and market share by organization, as well as market rate, competitive landscape, and recent developments, transaction, growth, sale, and market shares of top companies.

⏩ Companies Profiles: The Global Biologics Contract Manufacturing market's leading players are studied based on sales, main products, gross profit margin, revenue, price, and growth production.

⏩ Market Outlook by Region: The report goes through gross margin, sales, income, supply, market share, CAGR, and market size by region in this segment. North America, Europe, Asia Pacific, Middle East & Africa, and South America are among the regions and countries studied in depth in this study.

⏩ Market Segments: It contains the deep research study which interprets how different end-user/application/type segments contribute to the Biologics Contract Manufacturing Market.

⏩ Market Forecast: Production Side: In this part of the report, the authors have focused on production and production value forecast, key producers forecast, and production and production value forecast by type.

⏩ Research Findings: This section of the report showcases the findings and analysis of the report.

⏩ Conclusion: This portion of the report is the last section of the report where the conclusion of the research study is provided.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription

People Also Ask:

◆ How big is the Biologics Contract Manufacturing Market in 2025?
◆ What is the projected growth rate of the Biologics Contract Manufacturing Market through 2033?
◆ Who are the key players in the Biologics Contract Manufacturing Market?
◆ Which region is expected to dominate the industry during the forecast period?

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.